HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Edward A Sausville Selected Research

NF-kappa B (NF-kB)

12/2005Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
2/2005The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Edward A Sausville Research Topics

Disease

70Neoplasms (Cancer)
01/2024 - 01/2002
21Leukemia
01/2019 - 12/2002
12Breast Neoplasms (Breast Cancer)
04/2016 - 01/2002
11Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2020 - 12/2003
9Carcinoma (Carcinomatosis)
04/2016 - 02/2002
5Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2020 - 10/2003
5Ovarian Neoplasms (Ovarian Cancer)
12/2013 - 09/2003
5BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
06/2013 - 01/2002
4Glioma (Gliomas)
05/2017 - 08/2002
4Prostatic Neoplasms (Prostate Cancer)
01/2016 - 12/2006
4Squamous Cell Carcinoma of Head and Neck
12/2005 - 11/2002
4Melanoma (Melanoma, Malignant)
08/2005 - 04/2004
3Diarrhea
11/2014 - 02/2003
3Lymphoma (Lymphomas)
01/2010 - 06/2005
3Hypoxia (Hypoxemia)
09/2005 - 08/2002
3Neoplasm Metastasis (Metastasis)
08/2005 - 10/2003
2Philadelphia Chromosome
01/2019 - 07/2011
2Hyperglycemia
04/2016 - 01/2010
2Hematologic Neoplasms (Hematological Malignancy)
05/2014 - 02/2002
2Ovarian Epithelial Carcinoma
12/2013 - 11/2012
2Constipation
02/2011 - 12/2009
2Myeloid Leukemia (Leukemia, Myelocytic)
03/2009 - 04/2007
2Kaposi Sarcoma (Kaposi's Sarcoma)
08/2006 - 04/2004
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2005 - 03/2002
2Adenocarcinoma
08/2005 - 08/2004
1Hepatocellular Carcinoma (Hepatoma)
01/2024
1Hypersensitivity (Allergy)
01/2020
1Pancreatitis
01/2020
1Thrombosis (Thrombus)
01/2020

Drug/Important Bio-Agent (IBA)

15Proteins (Proteins, Gene)FDA Link
04/2015 - 02/2002
97-hydroxystaurosporine (UCN 01)IBA
10/2013 - 11/2002
8NSC 680410IBA
12/2006 - 01/2002
7Antineoplastic Agents (Antineoplastics)IBA
01/2017 - 01/2002
7Cyclin-Dependent Kinases (cdk Proteins)IBA
10/2013 - 01/2002
7entinostat (MS 275)IBA
04/2007 - 02/2002
6Phosphotransferases (Kinase)IBA
01/2024 - 01/2002
6tanespimycin (17AAG)IBA
07/2010 - 09/2003
6alvocidib (flavopiridol)IBA
01/2005 - 05/2002
5Tyrosine Kinase InhibitorsIBA
01/2019 - 12/2002
5perifosineIBA
11/2014 - 03/2002
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2007 - 12/2002
52- (4- amino- 3- methylphenyl)- 5- fluorobenzothiazoleIBA
07/2006 - 02/2002
5Messenger RNA (mRNA)IBA
07/2006 - 09/2003
4DNA (Deoxyribonucleic Acid)IBA
05/2017 - 09/2004
4Folic Acid (Vitamin M)FDA LinkGeneric
12/2013 - 12/2009
4EC145IBA
12/2013 - 12/2009
4Histone Deacetylase InhibitorsIBA
04/2007 - 01/2005
4tyrphostin AG957IBA
12/2006 - 12/2002
4Cytochrome P-450 CYP1A1 (CYP1A1)IBA
07/2006 - 12/2003
3Asparaginase (Elspar)FDA Link
01/2020 - 05/2014
3NaphthoquinonesIBA
01/2017 - 01/2016
3Biomarkers (Surrogate Marker)IBA
05/2013 - 11/2002
3AlkaloidsIBA
11/2012 - 12/2009
3Imatinib Mesylate (Gleevec)FDA Link
07/2011 - 01/2002
3Cytarabine (Cytosar-U)FDA LinkGeneric
03/2009 - 12/2002
3benzothiazoleIBA
07/2006 - 01/2002
317- (dimethylaminoethylamino)- 17- demethoxygeldanamycinIBA
12/2005 - 08/2005
3Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
02/2005 - 01/2002
3Complementary DNA (cDNA)IBA
02/2004 - 03/2003
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2003 - 02/2002
2blinatumomabIBA
01/2019 - 01/2019
2Glutamine (L-Glutamine)FDA Link
01/2018 - 05/2014
2ErbB Receptors (EGF Receptor)IBA
04/2016 - 09/2007
2Reactive Oxygen Species (Oxygen Radicals)IBA
01/2016 - 12/2003
2Proteasome InhibitorsIBA
10/2013 - 12/2005
2Proteasome Endopeptidase Complex (Proteasome)IBA
10/2013 - 12/2005
2LigandsIBA
11/2012 - 01/2006
2HydrazinesIBA
11/2012 - 12/2009
2Insulin (Novolin)FDA Link
01/2010 - 11/2004
2Integrin beta3 (GPIIIa)IBA
11/2009 - 06/2009
2arginyl-glycyl-aspartic acidIBA
11/2009 - 06/2009
2Heat-Shock Proteins (Heat-Shock Protein)IBA
11/2009 - 09/2003
2geldanamycinIBA
11/2009 - 06/2009
2N-(2-hydroxypropyl)methacrylamideIBA
11/2009 - 06/2009
2hydroxypropyl methacrylateIBA
11/2009 - 06/2009
2Drug CombinationsIBA
03/2009 - 10/2003
2Monoclonal AntibodiesIBA
09/2007 - 11/2003
2G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
08/2006 - 04/2004
2Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
07/2006 - 02/2002
2Peptides (Polypeptides)IBA
01/2006 - 10/2004
2NF-kappa B (NF-kB)IBA
12/2005 - 02/2005
2Cyclin D1IBA
08/2005 - 05/2002
2NSC 674495IBA
12/2004 - 01/2002
21,1'- ((propane- 1,3- diyl)dioxy)bis(7- methoxy- 2- methylidene- 1,2,3,10,11,11a- hexahydro- 5H- pyrrolo(2,1- c)(1,4)benzodiazepin- 5,11- dione)IBA
09/2004 - 09/2004
2Cisplatin (Platino)FDA LinkGeneric
09/2004 - 07/2004
2ElementsIBA
06/2004 - 08/2002
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
02/2004 - 09/2003
2CaspasesIBA
02/2004 - 09/2003
2AntibodiesIBA
11/2003 - 06/2003
2Protein Kinase CIBA
09/2003 - 11/2002
1Sorafenib (BAY 43-9006)FDA Link
01/2024
1navitoclaxIBA
01/2024
1pegaspargase (Oncaspar)FDA Link
01/2020
1ponatinibIBA
01/2019

Therapy/Procedure

20Therapeutics
01/2019 - 08/2002
6Drug Therapy (Chemotherapy)
01/2019 - 12/2002
3Aftercare (After-Treatment)
02/2004 - 02/2002
2Induction Chemotherapy
01/2020 - 07/2015
2Radiotherapy
06/2013 - 12/2005
2Combination Drug Therapy (Combination Chemotherapy)
03/2009 - 11/2005